Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion

Cancer Letters

Volumn 283, Issue 1, 2009, Pages 29-35

  Singh, Shailesh ^a   Singh, Rajesh ^a   Sharma, Praveen K ^a   Singh, Udai P ^b   Rai, Shesh N ^a,c   Chung, Leland W K ^d   Cooper, Carlton R ^e   Novakovic, Kristian R ^a   Grizzle, William E ^f   Lillard Jr , James W ^a,g  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF DELAWARE   (United States)

^f University of Alabama at Birmingham   (United States)

^g MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion; Chemokine; Integrin; Invasion; Prostate

Indexed keywords

CXCL13 CHEMOKINE; INTEGRIN; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

BONE AND BONES; CELL ADHESION; CELL LINE, TUMOR; CHEMOKINE CXCL13; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTEGRINS; INTERLEUKIN-6; MALE; NEOPLASM INVASIVENESS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, CXCR5; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650429727     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.022     Document Type: Article

References (44)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M. Cancer statistics. CA Cancer J. Clin. 58 (2008) 71-96
2. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J. Clin. 49 (1999) 8-31
3. Nicolson G.L. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastas. Rev. 12 (1993) 325-343
4. Roh K.J., Kim D.J., Kim D.W., and Wang J.M. Chemokines and their role in tumor growth and metastasis. J. Bone Joint Surg. Br. 80 (1998) 1005-1008
5. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., and Coltman Jr. C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New Engl. J. Med. 350 (2004) 2239-2246
6. Hankey B.F., Feuer E.J., Clegg L.X., Hayes R.B., Legler J.M., Prorok P.C., Ries L.A., Merrill R.M., and Kaplan R.S. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J. Natl. Cancer Inst. 91 (1999) 1017-1024
7. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J. Urol. 172 (2004) 1297-1301
8. Coleman R.E., and Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55 (1987) 61-66
9. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2 (2002) 584-593
10. Charhon S.A., Chapuy M.C., Delvin E.E., Valentin-Opran A., Edouard C.M., and Meunier P.J. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51 (1983) 918-924
11. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
12. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
13. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., and McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62 (2002) 1832-1837
14. Singh S., Singh U.P., Grizzle W.E., and Lillard J.W. CXCL12-CXCR4 interactions modulates prostate cancer cell migration, metalloproteinase expression and invasion. Lab. Invest. 84 (2004) 1666-1676
15. Shulby S.A., Dolloff N.G., Stearns M.E., Meucci O., and Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64 (2004) 4693-4698
16. Singh S., Singh U.P., Stiles J.K., Grizzle W.E., and Lillard J.W. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin. Cancer Res. 10 (2004) 8743-8750
17. Heresi G.A., Wang J., Taichman R., Chirinos J.A., Regalado J.J., Lichtstein D.M., and Rosenblatt J.D. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol 23 (2005) 261-267
18. Engl T., Relja B., Blumenberg C., Muller I., Ringel E.M., Beecken W.-D., Jonas D., and Blaheta R.A. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci. 78 (2006) 1784-1793
19. Vaday G.G., Peehl D.M., Kadam P.A., and Lawrence D.M. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 (2006) 124-134
20. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K.J., Mehra R., Loberg R., and Taichman R.S. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 283 (2008) 4283-4294
21. Wedel S.A., Raditchev I.N., Jones J., Juengel E., Engl T., Jonas D., and Blaheta R.A. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol. Med. Rep. 1 (2008) 257-262
22. S. Singh, R. Singh, U.P. Singh, S.N. Rai, K.R. Novakovic, L.W.K. Chung, P.J. Didier, W.E. Grizzle, and J.W. Lillard Jr., Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and prostate cancer cell lines, Int. J. Cancer, accepted for publication.
23. Michalaki V., Syrigos K., Charles P., and Waxman J. Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 90 (2004) 2312-2316
24. Hoosein N.M. Neuroendocrine and immune mediators in prostate cancer progression. Front. Biosci. 3 (1998) D1274-D1279
25. Siegall C.B., Schwab G., Nordan R.P., FitzGerald D.J., and Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 50 (1990) 7786-7788
26. Siegsmund M.J., Yamazaki H., and Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J. Urol. 151 (1994) 1396-1399
27. Nakashima J., Tachibana M., Ueno M., Miyajima A., Baba S., and Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin. Cancer Res. 4 (1998) 1743-1748
28. Cross N.A., Papageorgiou M., and Eaton C.L. Bone marrow stromal cells promote growth and survival of prostate cancer cells. Biochem. Soc. Trans. 35 (2007) 698-700
29. Tenta R., Sourla A., Lembessis P., Luu-The V., and Koutsilieris M. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm. Metab. Res. 37 (2005) 593-601
30. Lu Y., Zhang J., Dai J., Dehne L.A., Mizokami A., Yao Z., and Keller E.T. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin. Exp. Metastas. 21 (2004) 399-408
31. Burger M., Glodek A., Hartmann T., Schmitt-Graff A., Silberstein L.E., Fujii N., Kipps T.J., and Burger J.A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22 (2003) 8093-8101
32. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J. Urol. 162 (1999) 293-306
33. Stamey T.A., Ekman P.E., Blankenstein M.A., Cooper E.H., Kontturi M., Lilja H., Oesterling J.E., Stenman U.H., and Turkes A. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand. J. Urol. Nephrol. 162 Suppl. (1994) 73-87
34. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., Spangberg A., Busch C., Nordling S., Garmo H., Palmgren J., Adami H.O., Norlen B.J., and Johansson J.E. Scandinavian prostate cancer group study radical prostatectomy versus watchful waiting in early prostate cancer. New Engl. J. Med. 352 (2005) 1977-1984
35. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., Scardino P.T., and Pearson J.D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
36. Raaijmakers R., Wildhagen M.F., Ito K., Paez A., de Vries S.H., Roobol M.J., and Schroder F.H. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63 (2004) 316-320
37. Ducy P., Schinke T., and Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 289 (2000) 1501-1504
38. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276 (1997) 71-74
39. Lisignoli G., Tonehuzzi S., Piacentini A., Cattini L., Lenti A., Tschon M., Cristino S., Grassi F., and Facchini A. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and b-N-acetylhexosaminidase release. J. Cell Physiol. 194 (2002) 71-79
40. Gamble J.G., Haimson R., and Smith R.L. Glucosaminidase, galactosaminidase, and glucuronidase in the growth plate. J. Orthop. Res. 8 (1990) 764-768
41. Bodo M., Carinci P., Venti G., Giammarioli M., Donti E., Stabellini G., Paludetti G., and Becchetti E. Glycosaminoglycan metabolism and cytokine release in normal and otosclerotic human bone cells interleukin-1 treated. Connect. Tissue Res. 36 (1997) 231-240
42. Witkowski C.M., Rabinovitz I., Nagle R.B., Affinito K.S., and Cress A.E. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J. Cancer Res. Clin. Oncol. 119 (1993) 637-644
43. Romanov V.I., and Goligorsky M.S. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate 39 (1999) 108-118
44. Cooper C.R., Bhatia J.K., Muenchen H.J., McLean L., Hayasaka S., Taylor J., Poncza P.J., and Pienta K.J. The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin. Exp. Metastas. 19 (2002) 25-33